Economics of the clinical management of lung cancer in France: an analysis using a Markov model
| Autor: | Laurent Molinier, Christophe Combescure, Bruno Housset, Jean-Pierre Daurès, Christos Chouaid, A. Vergnenegre |
|---|---|
| Přispěvatelé: | Epidémiologie des maladies infectieuses et modélisation (ESIM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), C Chouaïd, Molinier L, C Combescure, JP Daurès, B Housset, SCHILLER A . |
| Rok vydání: | 2004 |
| Předmět: |
Male
Oncology Cancer Research Lung Neoplasms Palliative care medicine.medical_treatment MESH: Health Care Surveys MESH: Aged 80 and over 0302 clinical medicine Carcinoma Non-Small-Cell Lung Antineoplastic Combined Chemotherapy Protocols Economic analysis 030212 general & internal medicine Carcinoma Small Cell Stage (cooking) health care economics and organizations Aged 80 and over MESH: Aged MESH: Middle Aged Palliative Care Respiratory disease MESH: Carcinoma Small Cell Health Care Costs Middle Aged Markov Chains 3. Good health MESH: Antineoplastic Combined Chemotherapy Protocols Models Economic 030220 oncology & carcinogenesis Costs and Cost Analysis Female MESH: Palliative Care France management medicine.medical_specialty Locally advanced MESH: Health Care Costs MESH: Costs and Cost Analysis economic analysis Clinical 03 medical and health sciences MESH: Markov Chains Internal medicine medicine Carcinoma Humans Lung cancer Aged MESH: Models Economic Chemotherapy MESH: Humans business.industry medicine.disease Markov model MESH: Male MESH: Lung Neoplasms respiratory tract diseases Surgery MESH: France lung cancer Health Care Surveys [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie business MESH: Female MESH: Carcinoma Non-Small-Cell Lung |
| Zdroj: | British Journal of Cancer British Journal of Cancer, Cancer Research UK, 2004, 90 (2), pp.397-402. ⟨10.1038/sj.bjc.6601547⟩ British Journal of Cancer, 2004, 90 (2), pp.397-402. ⟨10.1038/sj.bjc.6601547⟩ |
| ISSN: | 1532-1827 0007-0920 |
| DOI: | 10.1038/sj.bjc.6601547 |
| Popis: | International audience; To evaluate, according to the histologic type and initial stage, the mean cost (MC) of managing patients with lung cancer and the costs of the different management phases. A Markov approach was used to model these costs, based on the management of a representative nation-wide sample of 428 patients with newly diagnosed lung cancer. The 18-month MC ranged from US$ 20 691 (95% CI: 5777-50 380 for diffuse non-small-cell lung cancer (NSCLC) to US$ 31 833 (95% CI: 15 866-64 455) for localised small-cell lung cancer (SCLC); first-line treatment costs ranged from 33.8% of MC for medically inoperable localised NSCLC to 74.6% for diffuse SCLC; second- or third-line treatment costs ranged from 7.8% of MC for surgically treated localised NSCLC to 32% for locally advanced NSCLC; and the cost of palliative care ranged from 9.1% of MC for locally advanced NSCLC to 39.9% for medically inoperable localised NSCLC. The cost of first-line chemotherapy and the percentage of actively treated patients impacted more on MC than did the cost of second- or third-line chemotherapy regimens or the cost of palliative care. In conclusion, this model provides a robust economic analysis of the cost of lung cancer management, and will be useful for assessing the economic consequences of future changes in patient management. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|